Table 4.
Comparison of HE4, CA125, ROMA, and CPH-I among BOT I+II and EOC I+II group stratification by pathology.
| BOT I+II | EOC I+II | |||||||
|---|---|---|---|---|---|---|---|---|
| Serous | Mucinous | Endometrioid | Clear cell | Serous | Mucinous | Endometrioid | Clear cell | |
| HE4 (pmol/L) | 49.8 (42.5-57.9) | 45.3 (38.9-53.0) | 57.4 (47.4-89.9) | 37.8 (31.5-42.7) | 130.6 (72.6-230.5)∗ | 57.3 (47.3-65.1)∗ | 91.9 (55.6-221.0) | 64.8 (50.6-82.3) |
| CA125 (U/mL) | 39.4 (19.6-86.5) | 25.5 (17.9-37.2) | 54.2 (24.8-127.3) | 29.6 (22.7-53.5) | 105.8 (55.5-392.9)∗ | 54.7 (16.0-117.8) | 103.5 (32.1-251.8) | 95.1 (34.5-180.3) |
| ROMA (%) | 8.2 (5.5-12.5) | 6.1 (4.2-9.6) | 11.0 (7.0-43.8) | 8.59 (3.0-18.4) | 59.7 (23.5-81.9)∗ | 11.2 (7.1-14.0)# | 45.1 (10.6-82.0) | 21.2 (9.4-32.0) |
| CPH-I (%) | 1.8 (1.2-4.6) | 1.0 (0.6-2.0) | 1.9 (1.4-11.4) | 1.5 (0.9-2.3) | 30.4 (7.8-56.1)∗ | 3.0 (1.7-7.9)∗ | 11.4 (2.5-57.0) | 7.3 (3.1-14.6) |
Note: data are presented as the median (interquartile range). ∗P < 0.01 and #P < 0.05 EOC I+II vs. BOT I+II in corresponding subgroups. Abbreviations: BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.